Biology & Ecology
Biology
Gram Statusgram-positive
Oxygen Toleranceobligate anaerobe
Morphologycoccus
Key Traits
- cellulose-degrading
Ecology
Primary Nichesgut
Reservoiranimal, human
Clinical Profile
Pathobiont
yes
no
context dependent
unknown
Clinical Rolesprotective commensal
Typical Specimenstool
Risk Contextsmelanoma patients receiving immune checkpoint inhibitor therapy (ICB)
AMR Highlights
none documented
Virulence Factors
none documented
Clinical Associations:
E2
E3 — Strong human clinical evidence
E2 — Moderate human evidence
E1 — Limited / preliminary
Ruminococcus flavefaciens was identified in transkingdom multi-omic network analysis as enriched in responders (objective response or stable disease >12 months) to FMT plus pembrolizumab in a Phase 2 trial of 15 PD-1-refractory advanced melanoma patients, and negatively correlated with circulating CXCL8 (IL-8), an immunosuppressive cytokine elevated in non-responders.
PMID:
33542131
Last reviewed: 2026-04-02
Evidence Timeline
Related Taxa
Shared Niche = same body site
Shared Risk = same vulnerable population
ⓘ